Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Investing Activities (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Cash from Investing Activities data on record, last reported at -$108000.0 in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 440.0% year-over-year to -$108000.0; the TTM value through Dec 2025 reached -$313000.0, up 22.33%, while the annual FY2025 figure was -$313000.0, 22.33% up from the prior year.
  • Cash from Investing Activities reached -$108000.0 in Q4 2025 per APLS's latest filing, up from -$148000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $179.6 million in Q3 2021 and bottomed at -$271.9 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is $16.1 million, with a median of -$47000.0 recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 93484.62% in 2021, then tumbled 600.0% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $85.0 million in 2021, then surged by 46.07% to $124.1 million in 2022, then crashed by 100.0% to $4000.0 in 2023, then crashed by 600.0% to -$20000.0 in 2024, then crashed by 440.0% to -$108000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$108000.0 in Q4 2025, -$148000.0 in Q3 2025, and -$49000.0 in Q2 2025.